Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses.

INTRODUCTION: The role of human albumin (HA) infusion in cirrhotic patients has been increasingly recognized. This paper aims to summarize the evidence from meta-analyses regarding HA infusion for the management of cirrhosis and its complications. METHODS: A systematic search in the PubMed, EMBASE, and Cochrane library databases, and in reference lists was conducted. All relevant meta-analyses were identified and their findings were reviewed. The Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) checklist was used to evaluate the methodological quality and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system to assess the quality of evidence for significant outcomes. RESULTS: Among 300 papers initially identified, 18 meta-analyses have been included. Short- and long-term HA infusion at high doses decreased the mortality of patients with decompensated cirrhosis. In cirrhotic patients with ascites, long-term HA infusion reduced the recurrence of ascites, but not mortality. In cirrhotic patients undergoing large-volume paracentesis (LVP), HA infusion reduced the incidence of post-paracentesis circulatory dysfunction and hyponatremia, but not mortality or renal impairment. In cirrhotic patients with overt hepatic encephalopathy (HE), HA infusion improved the severity of overt HE, but not overall mortality. In cirrhotic patients with spontaneous bacterial peritonitis (SBP), but not those with non-SBP infections, HA infusion reduced the mortality and renal impairment. In cirrhotic patients with type-1 hepatorenal syndrome (HRS), an increment of 100 g in cumulative HA dose increased 1.15-fold survival, but not HRS reversal. In these meta-analyses, the quality of methodology was low or critically low, and that of the evidence was from very low to moderate. CONCLUSIONS: Based on the limited evidence from these meta-analyses, HA infusion appears to be beneficial in cirrhotic patients with ascites, overt HE, and SBP and in those undergoing LVP, but not in those with non-SBP infections.

Anthropometric measures associated with sarcopenia in outpatients with liver cirrhosis.

AIM: The present study aimed to identify variables associated with sarcopenia in cirrhotic outpatients using clinical data, anthropometric measures and lab tests. In a single centre prospective study, 261 cirrhotic outpatients were followed on average for 2 years. The diagnostic criteria of sarcopenia were applied according to the current guidelines, combining muscle strength and appendicular muscle mass index. METHODS: Age, sex, liver disease aetiology and the Model of End-Stage Liver Disease score were included as independent variables, as well as mid-arm circumference (MAC), body mass index and triceps skinfold. Multiple logistic regression was applied including all independent variables (maximum model). Then, the analysis was performed only with the variables that were significant in the first analysis (parsimonious model). Once the variable most related to sarcopenia was determined by the two models, the area under the receiver operator characteristic curve was calculated. Mortality rates were described for patients with and without sarcopenia. RESULTS: Sarcopenia was diagnosed in 14 subjects (5.36%), and the variable best associated with sarcopenia was MAC (P < 0.01). The 1-year mortality rate of 35.71% found among subjects with sarcopenia was not significantly higher (P = 0.07) than the 15.38% observed among those without this condition. CONCLUSIONS: Before examinations requiring ionising radiation, patients with cirrhosis can be submitted to simple screening tools to identify those who have a high risk of sarcopenia, thus promoting a cost-effective assessment.

Cardiac Cachexia: Perspectives for Prevention and Treatment / Caquexia Cardíaca: Perspectivas para a Prevenção e Tratamento

Abstract Cachexia is a prevalent pathological condition associated with chronic heart failure. Its occurrence predicts increased morbidity and mortality independent of important clinical variables such as age, ventricular function, or heart failure functional class. The clinical consequences of cachexia are dependent on both weight loss and systemic inflammation, which accompany cachexia development. Skeletal muscle wasting is an important component of cachexia; it often precedes cachexia development and predicts poor outcome in heart failure. Cachexia clinically affects several organs and systems. It is a multifactorial condition where underlying pathophysiological mechanisms are not completely understood making it difficult to develop specific prevention and treatment therapies. Preventive strategies have largely focused on muscle mass preservation. Different treatment options have been described, mostly in small clinical studies or experimental settings. These include nutritional support, neurohormonal blockade, reducing intestinal bacterial translocation, anemia and iron deficiency treatment, appetite stimulants, immunomodulatory agents, anabolic hormones, and physical exercise regimens. Currently, nonpharmacological therapy such as nutritional support and physical exercise are considered central to cachexia prevention and treatment.

Resumo Caquexia é condição patológica prevalente em pacientes com insuficiência cardíaca (IC) associada. Sua ocorrência constitui marcador de gravidade da doença e está associada a aumento da morbidade e mortalidade independentemente de variáveis clínicas importantes como idade, função ventricular ou classe funcional da IC. As consequências clínicas da caquexia dependem tanto da perda de peso como da inflamação sistêmica que acompanha seu desenvolvimento. Perda da musculatura esquelética é importante componente da caquexia; ela frequentemente precede o desenvolvimento desta condição e está associada a mau prognóstico da IC. A caquexia afeta vários órgãos e sistemas. Sua origem é multifatorial; como os mecanismos fisiopatológicos envolvidos em seu desenvolvimento não estão completamente entendidos, há grande dificuldade no desenvolvimento de terapia específica para a prevenção e tratamento. Estratégias para a prevenção visam, principalmente, a preservação da massa muscular. Diferentes opções de tratamento têm sido descritas, a maioria delas avaliada em estudos experimentais ou pequenos estudos clínicos. Estas incluem suporte nutricional, bloqueio de sistemas neuro-hormonais, redução de translocação bacteriana intestinal, tratamento da anemia e ferrodeficiência, estimulantes de apetite, agentes imunomodulatórios, hormônios anabólicos, e diferentes programas de exercícios físicos. Atualmente, a terapia não farmacológica como o suporte nutricional e exercícios físicos tem sido considerada de grande importância na prevenção e tratamento da caquexia associada à IC.

Cardiac Cachexia: Perspectives for Prevention and Treatment.

Cachexia is a prevalent pathological condition associated with chronic heart failure. Its occurrence predicts increased morbidity and mortality independent of important clinical variables such as age, ventricular function, or heart failure functional class. The clinical consequences of cachexia are dependent on both weight loss and systemic inflammation, which accompany cachexia development. Skeletal muscle wasting is an important component of cachexia; it often precedes cachexia development and predicts poor outcome in heart failure. Cachexia clinically affects several organs and systems. It is a multifactorial condition where underlying pathophysiological mechanisms are not completely understood making it difficult to develop specific prevention and treatment therapies. Preventive strategies have largely focused on muscle mass preservation. Different treatment options have been described, mostly in small clinical studies or experimental settings. These include nutritional support, neurohormonal blockade, reducing intestinal bacterial translocation, anemia and iron deficiency treatment, appetite stimulants, immunomodulatory agents, anabolic hormones, and physical exercise regimens. Currently, nonpharmacological therapy such as nutritional support and physical exercise are considered central to cachexia prevention and treatment.

Influence of post-transplant immunosuppressive therapy on gastrointestinal transit using biomagnetic method: a pilot study.

BACKGROUND: Immunosuppressive therapy after kidney transplant is necessary to prevent allograft rejection and it is the cause of several gastrointestinal (GI) disorders that have been scantily studied. OBJECTIVES: This study was aimed at investigating the influence of triple immunosuppressive therapy on GI transit in renal transplant patients by employing a biomagnetic technique. METHODS: Twenty-one renal transplant patients underwent triple therapy, which included either tacrolimus (TAC) or cyclosporin A (CsA) associated with prednisone and azathioprine. They were all evaluated, and fifteen other healthy individuals formed the control group. After a standardized meal, GI transit of magnetic markers was assessed using Alternating Current Biosusceptometry (ACB). RESULTS: Patients taking TAC had significantly accelerated gastric emptying and colonic arrival (p ≤ 0.001) when compared with those taking CsA and those in the control group. However, no differences were observed in small bowel transit among the groups studied. Overall, the inter-subject coefficients of variation for gastrointestinal transit parameters were higher for the TAC group and similar for the CsA and control groups. CONCLUSION: This study demonstrated that ACB is a suitable methodology when evaluating the influence of different immunosuppressive therapies on gastrointestinal transit after renal transplantation. Pronounced inter-individual variation was found in patients treated with tacrolimus, thus showing the prokinetic effect of this drug on GI motility. Studies of motility patterns in this population could be useful as complementary information toward determining the mechanisms and the relationship between motility and therapeutic doses.

Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients.

Reports on the clinical course of mycophenolic acid (MPA)-related colitis in kidney transplant recipients are scarce. This study aimed at assessing MPA-related colitis incidence, risk factors, and progression after kidney transplantation. All kidney transplant patients taking MPA who had colonic biopsies for persistent chronic diarrhea, between 2000 and 2012, at the Kidney Transplantation Unit of Botucatu Medical School Hospital, Brazil, were included. Cytomegalovirus (CMV) immunohistochemistry was performed in all biopsy specimens. Data on presenting symptoms, medications, immunosuppressive drugs, colonoscopic findings, and follow-up were obtained. Of 580 kidney transplant patients on MPA, 34 underwent colonoscopy. Colonoscopic findings were associated with MPA usage in 16 patients. The most frequent histologic patterns were non-specific colitis (31.3%), inflammatory bowel disease (IBD)-like colitis (25%), normal/near normal (18.8%), graft-versus-host disease-like (18.8%), and ischemia-like colitis (12.5%). All patients had persistent acute diarrhea and weight loss. Six of the 16 MPA-related diarrhea patients (37.5%) showed acute dehydration requiring hospitalization. Diarrhea resolved when MPA was switched to sirolimus (50%), discontinued (18.75%), switched to azathioprine (12.5%), or reduced by 50% (18.75%). No graft loss occurred. Four patients died during the study period. Late-onset MPA was more frequent, and no correlation with MPA dose or formulation was found.

Acute fatty liver of pregnancy associated with severe acute pancreatitis: A case report.

Acute fatty liver of pregnancy is a rare disease that affects women in the third trimester of pregnancy. Although infrequent, the disease can cause maternal mortality. The diagnosis is not always clear until the pregnancy is terminated, and significant complications, such as acute pancreatitis, can occur. Pancreatic involvement typically only occurs in severe cases after the development of hepatic and renal impairment. To date, little knowledge is available regarding how the disease causes pancreatitis. Treatment involves supportive measures and pregnancy interruption. In this report, we describe a case of a previously healthy 26-year-old woman at a gestational age of 27 wk and 6 d who was admitted with severe abdominal pain and vomiting. This case illustrates the clinical and laboratory overlap between acute fatty liver of pregnancy and pancreatitis, highlighting the difficulties in differentiating each disease. Furthermore, the hypothesis for this overlapping is presented, and the therapeutic options are discussed.

Diagnóstico diferencial entre doença de crohn e hidradenite supurativa: relato de caso / Differential diagnosis between crohn's disease and hidradenitis supurativa: case report

A doença de Crohn é uma doença inflamatória intestinal crônica com inflamação transmural segmentar, que pode complicar com formação de fístulas e abscessos. A hidradenite supurativa (HS) é caracterizada por abscessos recorrentes e dolorosos, com predileção por áreas ricas em glândulas apócrinas como as regiões axilares, inguinais e perineal. O diagnóstico diferencial entre estas doenças é difícil e pode comprometer o tratamento. Relatamos o caso de C.R.M.A., 40 anos, feminina, branca, com doença de Crohn íleocolônica com fístula perianal e retovaginal há 12 anos, em terapia biológica desde maio 2010. Em setembro de 2010 apresentou abscesso em glúteo direito com saída de secreção purulenta refratária ao uso de ciprofloxacino e metronidazol. Ultrassonografia apresentando coleção de 30 cm3 em região glútea direita. A hipótese diagnóstica foi HS e a paciente foi submetida à ressecção cirúrgica em bloco (10 x 2 cm), com cicatrização por segunda intenção. Realizou enxerto de pele em dezembro de 2010 sem sucesso. Retornou em janeiro de 2011 com nova fístula no local da ressecção, compatível com doença de Crohn. Em fevereiro de 2011 foi submetida à drenagem dos abscessos e colocação de setons nas fístulas perianais. Atualmente em terapia biológica, com boa evolução das fístulas. A prevalência da HS varia de 0,3 a 4% da população em geral. A axila é a região mais afetada e as lesões perianais estão associadas com maior debilidade. Há relatos na literatura de associação entre a HS e a doença de Crohn de forma esporádica, e novos estudos são necessários para avaliar uma patogênese em comum. O diagnóstico diferencial deve ser realizado em todos os casos para tratamento imediato, evitando-se, assim, as complicações e a piora da qualidade de vida do doente.

Crohn?s disease is a chronic inflammatory bowel disease with segmental transmural inflammation, which complicate with formation of fistulas and abscesses. The hidradenitis suppurativa (HS) is characterized by recurrent abscesses, with a predilection for areas rich in apocrine glands such as the axillary, inguinal and perineal. The differential diagnosis between these diseases is difficult and may compromise treatment. Report case: C.R.M.A., 40 year-old, female, white, ileal and colonic Crohn?s disease complicated with perianal and rectovaginal fistula for 12 years, treated with biological therapy since May 2010. In Sep/2010 presented with an abscess in the buttock D with purulent discharge refractory to the use of ciprofloxacin and metronidazole. USG: collection of 30 cm3 in buttock D. The diagnosis was HS and the patient underwent extensive surgical removal of the affected areas (10 x 2 cm) with healing by secondary intention. Skin graft performed unsuccessfully in Dec/2010. The patient returned in jan/2011 with a new fistula at the site of resection, consistent with Crohn?s disease. In fev/2011 underwent drainage of abscesses and placement of setons in perianal fistulas. Currently in therapy with good biological evolution of fistulas. The prevalence of HS varies from 0.3 to 4% of the population in general. The axilla is the region most affected and perianal lesions are associated with greater weakness. There are published reports of association between HS and Crohn?s disease sporadically and further studies are needed to assess a common pathogenesis. The differential diagnosis should be performed in all cases planning immediate treatment, avoiding complications and worsening of the patient?s quality of life.

Caquexia associada à insuficiência cardíaca / Heart failure-induced cachexia

Pacientes com insuficiência cardíaca frequentemente desenvolvem estado de caquexia, que constitui fator independente de redução da sobrevida. Caquexia pode ser diagnosticada quando ocorre perda de peso corporal maior que 6% do peso habitual, na ausência de outras doenças. Embora sua fisiopatologia não esteja completamente esclarecida, vários fatores parecem estar envolvidos, como diminuição da ingestão alimentar, anormalidades do trato gastrointestinal, ativação imunológica e neuro-hormonal e alteração da relação entre processos anabólicos e catabólicos. Como não há terapia específica para a caquexia associada à insuficiência cardíaca, o tratamento baseia-se no suporte nutricional, bloqueio neuro-hormonal, controle do edema e anemia e exercícios físicos. Fármacos com propriedades imunomodulatórias e anabólicas encontram-se em investigação clínica e experimental.

Heart failure patients often develop cachexia, which is an independent factor for survival reduction. Cachexia can be diagnosed when there is loss of more than 6% of the body weight, in the absence of other diseases. Even though its pathophysiology has not yet been completely clarified, various factors seem to be involved, such as reduction in food consumption, gastrointestinal tract abnormalities, immunologic and neuro-hormonal activarion and changes in the relationship between anabolic and catabolic processes. Since there is not specific therapy for heart failure-induced cachexia, management is based on nutritional support, neuro-hormonal blockade, control of edema and anemia and exercise. Drugs with anabolic and immunomodulating properties are being evaluated and clinical and non-clinical trials.

Heart failure-induced cachexia.

Heart failure patients often develop cachexia, which is an independent factor for survival reduction. Cachexia can be diagnosed when there is loss of more than 6% of the body weight, in the absence of other diseases. Even though its pathophysiology has not yet been completely clarified, various factors seem to be involved, such as reduction in food consumption, gastrointestinal tract abnormalities, immunologic and neuro-hormonal activation and changes in the relationship between anabolic and catabolic processes. Since there is not specific therapy for heart failure-induced cachexia, management is based on nutritional support, neuro-hormonal blockade, control of edema and anemia and exercise. Drugs with anabolic and immunomodulating properties are being evaluated and clinical and non-clinical trials.

A análise morfométrica para avaliar a taxa de progressão da fibrose hepática na hepatite C crônica após o transplante renal: uma série de casos / Morphometric analysis to evaluate hepatic fibrosis progression rate in chronic hepatites C after kidney transplantation: a case serie study

O verdadeiro papel do transplante renal na progressão da fibrose hepática causada pelo vírus da hepatite C ainda é imprevisível. A avaliação histológica do fígado é a melhor forma para estimar a evolução da fibrose, embora a análise semiquantitativa traz limitações importantes. Objetivo: aplicar um ensaio morfométrico quantitativo sobre a progressão da fibrose hepática em pacientes renais crônicos com hepatite C. Métodos: trinta pacientes foram inicialmente avaliados, mas apenas sete foram incluídos. Eles foram submetidos à primeira biópsia perto da data do transplante e a segunda biópsia, pelo menos, quatro anos mais tarde. A terapia imunossupressora adotada em todos os casos foi a azatioprina e micofenolato. A taxa de progressão da fibrose (FPR) foi calculada antes e após a data da cirurgia de cada paciente, de acordo com a classificação de Metavir pontuação e análise morfométrica. Resultados: a FPR calculada pelo escore Metavir não mostrou diferença estatística entre pré e pós-transplante (p = 0,9). A FPR calculada pela análise morfométrica foi de 0,58 ± 0,78 antes do transplante e 3,0 ± 3,3 após a cirurgia, com significância estatística entre estes valores (p = 0,0026). Conclusão: na amostra avaliada, a progressão da fibrose hepática foi documentada e quantificada apenas pela análise morfométrica, que é uma abordagem promissora para avaliação histológica desses pacientes.

The real role of renal transplantation in hepatic fibrosis progression caused by hepatitis C virus is still unpredictable. Histological evaluation of the liver is the best form to estimate fibrosis evolution, although semiquantitative analysis carries important limitations. Objective: to apply a morphometric quantitative assay on hepatic fibrosis progression in renal recipients with hepatits C. Methods: thirty patients were initially evaluated, but only seven were included. They underwent the first biopsy near the transplantation date and the second biopsy at least 4 years later. The immunosuppressant therapy adopted in all cases was azatioprine and micofenolate. Fibrosis progression rate (FPR) was calculated before and after the surgery date in each patient according to Metavir score and morphometric analysis. Results: the FPR calculated by Metavir score showed no statistical difference between pre- and post-transplantation (p=0.9). The FPR calculated by the morphometric analysis was 0.58 ± 0.78 before transplantation and 3.0 ± 3.3 after the surgery, with statistical signifycance between these values (p=0.0026). Conclusion: in the sample assessed, the progression of hepatic fibrosis was documented and quantified only by the morphometric analysis, which is as a promising approach to histological evaluation of these patients.

Gastrointestinal changes associated to heart failure.

Over the last decade, several studies were conducted on the gastrointestinal changes associated to chronic heart failure. This article presents a literature review on the physiopathology and clinical consequences of pathological digestive changes of heart failure patients. Structural and functional abnormalities of the gastrointestinal tract, such as edema of absorptive mucosa and intestinal bacterial overgrowth, have been leading to serious clinical consequences. Some of these consequences are cardiac cachexia, systemic inflammatory activation and anemia. These conditions, alone or in combination, may lead to worsening of the pre-existing ventricular dysfunction. Although currently there is no therapy specifically earmarked for gastrointestinal changes associated to heart failure, the understanding of digestive abnormalities is germane for the prevention and management of systemic consequences.

Alterações gastrointestinais associadas a insuficiência cardíaca / Gastrointestinal changes associated to heart failure / Alteraciones gastrointestinales asociadas a la insuficiencia cardíaca

Na última década, foram realizados vários estudos sobre alterações gastrointestinais associadas a insuficiência cardíaca crônica. Neste artigo, apresentamos revisão da literatura sobre a fisiopatologia e consequências clínicas das alterações patológicas digestivas de pacientes com insuficiência cardíaca. Anormalidades estruturais e funcionais do trato gastrointestinal, como edema da mucosa absortiva e hipercrescimento bacteriano intestinal, têm sido responsabilizadas por graves consequências clínicas. Entre essas, destacam-se caquexia cardíaca, ativação inflamatória sistêmica e anemia. Essas condições, isoladamente ou em combinação, podem levar a piora da disfunção ventricular preexistente. Embora atualmente não haja terapêutica específica direcionada às alterações gastrointestinais associadas a insuficiência cardíaca, o entendimento das anormalidades digestivas é fundamental para sua prevenção e manejo das consequências sistêmicas.

Over the last decade, several studies were conducted on the gastrointestinal changes associated to chronic heart failure. This article presents a literature review on the physiopathology and clinical consequences of pathological digestive changes of heart failure patients. Structural and functional abnormalities of the gastrointestinal tract, such as edema of absorptive mucosa and intestinal bacterial overgrowth, have been leading to serious clinical consequences. Some of these consequences are cardiac cachexia, systemic inflammatory activation and anemia. These conditions, alone or in combination, may lead to worsening of the pre-existing ventricular dysfunction. Although currently there is no therapy specifically earmarked for gastrointestinal changes associated to heart failure, the understanding of digestive abnormalities is germane for the prevention and management of systemic consequences.

En la última década, fueron realizados varios estudios sobre las alteraciones gastrointestinales asociadas a la Insuficiencia Cardíaca Crónica. En este artículo, presentamos una revisión de la literatura sobre la fisiopatología y las consecuencias clínicas de las alteraciones patológicas digestivas de pacientes con insuficiencia cardíaca. Las anormalidades estructurales y funcionales del tracto gastrointestinal, como el edema de la mucosa absortiva y el hipercrecimiento bacteriano intestinal, han sido responsabilizadas de las graves consecuencias clínicas. Entre ellas destacamos la caquexia cardíaca, la activación inflamatoria sistémica y la anemia. Esas condiciones, aisladamente o de forma combinada, pueden conllevar al empeoramiento de la disfunción ventricular preexistente. Aunque actualmente no exista una terapéutica específica dirigida a las alteraciones gastrointestinales asociadas a la insuficiencia cardíaca, el entendimiento de las anormalidades digestivas es fundamental para su prevención y para el manejo de las consecuencias sistémicas.

Gastrointestinal cytomegalovirus disease in renal transplant recipients: a case series.

The purpose of this article was to report a series of 23 renal transplant recipients with histologically proven and immunohistochemically confirmed cytomegalovirus (CMV) lesions in the gastrointestinal tract (GIT) and to assess the risk factors associated with severe disease/mortality. CMV patients (n=23) were allocated into two groups: those who died (n=6) and those considered cured (n=17). Overall mortality rate was 26% (6/23). Initial symptoms suggestive of lower GIT involvement were observed in all death cases and in 35.3% of those cured (p=0.01). Enterorrhagia was seen in 83.3% of the patients who died. Death risk increased twofold (RR 2 [1.13-3.52], p=0.01) when symptoms of lower GIT involvement were initially observed and sixfold when enterrohagia was present (RR 6 [1.1-35.9], p=0.001). Among death cases, mean time at diagnosis was significantly more distant (2002±2.9×2008±1.6, p=0.04). The difference in mortality rates seen as service practices changed along the years demonstrates the importance of early diagnosis.

Acquired hepatocerebral degeneration and hepatic encephalopathy: correlations and variety of clinical presentations in overt and subclinical liver disease.

Acquired hepatocerebral degeneration (AHD) and hepatolenticular degeneration can have similar clinical presentations, but when a chronic liver disease and atypical motor findings coexist, the distinction between AHD and hepatic encephalopathy (HE) can be even more complicated. We describe three cases of AHD (two having HE) with different neuroimaging findings, distinct hepatic diseases and similar motor presentations, all presenting chronic arterial hypertension and weight loss before the disease manifestations. The diagnosis and physiopathology are commented upon and compared with previous reports. In conclusion, there are many correlations among HE, hepatolenticular degeneration and AHD, but the overlapping of AHD and HE could be more common depending on the clinical knowledge and diagnostic criteria adopted for each condition. Since AHD is not considered a priority that affects the liver transplant list, the prognosis in AHD patients remains poor, and flow interruption in portosystemic shunts must always be taken into account.

Acquired hepatocerebral degeneration and hepatic encephalopathy: correlations and variety of clinical presentations in overt and subclinical liver disease / Degeneração hepatocerebral adquirida e encefalopatia hepática: correlações e variedade de apresentações clínicas na doença hepática evidente e subclínica

Acquired hepatocerebral degeneration (AHD) and hepatolenticular degeneration can have similar clinical presentations, but when a chronic liver disease and atypical motor findings coexist, the distinction between AHD and hepatic encephalopathy (HE) can be even more complicated. We describe three cases of AHD (two having HE) with different neuroimaging findings, distinct hepatic diseases and similar motor presentations, all presenting chronic arterial hypertension and weight loss before the disease manifestations. The diagnosis and physiopathology are commented upon and compared with previous reports. In conclusion, there are many correlations among HE, hepatolenticular degeneration and AHD, but the overlapping of AHD and HE could be more common depending on the clinical knowledge and diagnostic criteria adopted for each condition. Since AHD is not considered a priority that affects the liver transplant list, the prognosis in AHD patients remains poor, and flow interruption in portosystemic shunts must always be taken into account.

A degeneração hepatocerebral adquirida (AHD) e a degeneração hepatolenticular podem ter apresentações clínicas semelhantes, mas quando uma doença hepática crônica e achados motores atípicos coexistem, a distinção entre AHD e encefalopatia hepática (HE) pode ser ainda mais complicada. Descrevemos três casos de AHD (dois tendo HE) com diferentes achados em neuroimagem, doenças hepáticas distintas e apresentações motoras semelhantes, todos com hipertensão arterial e perda de peso antes das manifestações motoras. O diagnóstico e a fisiopatologia são comentados e comparados com relatos prévios. Concluímos que existem muitas correlações entre HE, degeneração hepatolenticular e AHD, mas a sobreposição de HE e AHD pode ser mais comum dependendo do conhecimento clínico e da acurácia dos critérios diagnósticos adotados para cada enfermidade. Como a AHD não é considerada prioridade na lista de transplante hepático, o prognóstico dos pacientes com AHD permanece ruim, e a interrupção do fluxo nos shunts portossistêmicos deve ser sempre considerada.

Effects of meal size and proximal-distal segmentation on gastric activity.

AIM: To evaluate the effects of meal size and three segmentations on intragastric distribution of the meal and gastric motility, by scintigraphy. METHODS: Twelve healthy volunteers were randomly assessed, twice, by scintigraphy. The test meal consisted of 60 or 180 mL of yogurt labeled with 64 MBq (99m)Tc-tin colloid. Anterior and posterior dynamic frames were simultaneously acquired for 18 min and all data were analyzed in MatLab. Three proximal-distal segmentations using regions of interest were adopted for both meals. RESULTS: Intragastric distribution of the meal between the proximal and distal compartments was strongly influenced by the way in which the stomach was divided, showing greater proximal retention after the 180 mL. An important finding was that both dominant frequencies (1 and 3 cpm) were simultaneously recorded in the proximal and distal stomach; however, the power ratio of those dominant frequencies varied in agreement with the segmentation adopted and was independent of the meal size. CONCLUSION: It was possible to simultaneously evaluate the static intragastric distribution and phasic contractility from the same recording using our scintigraphic approach.

AC biosusceptometry technique to evaluate the gastrointestinal transit of pellets under influence of prandial state.

Multiparticulate dosage forms have been proposed when distal regions of gastrointestinal tract are desirable as target of drugs. It is known that physiological parameters might interfere with the processes related to the drug delivery and absorption and therefore, it is essential to evaluate the behavior of such delivery systems in vivo. The aim of this study was to propose the AC Biosusceptometry technique as a noninvasive and radiation free device to evaluate the gastrointestinal transit of a magnetic multiparticulate dosage form in healthy volunteers under fasting and fed conditions. Magnetic pellets were prepared by the powder layering method of ferrite on nonpareils sugar beads and coated by using Eudragit. Our data showed that the AC Biosusceptometry technique was able to monitoring the gastrointestinal transit of pellets presenting similar profiles as demonstrated by standard techniques. Food intake has markedly influenced the gastric emptying as well as the colon arrival and the small intestine transit of magnetic pellets.